| UHC Commercial Medical & Drug | Transcranial Magnetic Stimulation for Treating Physical Health Conditions – Commercial and Individual Exchange Medical Policy | 2026-02-01 |
| Meridian Illinois Medicaid Clinical | Brand Name Override | 2026-02-01 |
| Meridian Illinois Medicaid Clinical | Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists | 2026-02-01 |
| Meridian Illinois Medicaid Clinical | Abaloparatide (Tymlos) | 2026-02-01 |
| Meridian Illinois Medicaid Clinical | Abiraterone (Zytiga, Yonsa) | 2026-02-01 |
| Meridian Illinois Medicaid Clinical | Acalabrutinib (Calquence) | 2026-02-01 |
| Meridian Illinois Medicaid Clinical | Adagrasib (Krazati) | 2026-02-01 |
| Meridian Illinois Medicaid Clinical | Afamelanotide (Scenesse) | 2026-02-01 |
| Meridian Illinois Medicaid Clinical | Alglucosidase Alfa (Lumizyme) | 2026-02-01 |
| Meridian Illinois Medicaid Clinical | Alirocumab (Praluent) | 2026-02-01 |